An analysis of HER2 amplification in cervical adenocarcinoma: correlation with clinical outcomes and the International Endocervical Adenocarcinoma Criteria and Classification
Open Access
- 22 October 2020
- journal article
- research article
- Published by Wiley in The Journal of Pathology: Clinical Research
- Vol. 7 (1) , 86-95
Abstract
Few studies have explored HER2 status in cervical adenocarcinoma, particularly in the gastric‐type adenocarcinoma (GAC), a nonhuman‐papillomavirus‐related subtype with poor clinical outcomes. In this study, we investigated HER2 expression and amplification by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in 209 well annotated cervical adenocarcinomas diagnosed using the International Endocervical Adenocarcinoma Criteria and Classification. IHC identified HER2 protein expression in 57.4% (123/209) of adenocarcinomas, of which 62 were IHC 1+ (negative), 38 2+ (equivocal) and 23 3+ (positive). HER2 amplification was found in 13 cases (6.2%) including 10 with IHC 3+ and 3 with IHC 2+. Among all the major histotypes of cervical adenocarcinoma, HER2 amplification was most common in GAC cases with a frequency of 14.7% (5/34). Moreover, HER2 amplification was more frequently associated with 2018 International Federation of Gynecology & Obstetrics (FIGO) stage III/IV, perineural involvement and ovarian spread (p < 0.05) while IHC 3+ was more common in patients with lymphovascular invasion and ovarian involvement (p < 0.05). Survival analysis indicated that FIGO stage III/IV, GAC, and p53 overexpression were associated with poor disease‐specific survival and tumor recurrence (p < 0.05). In conclusion, HER2 amplification was present in a subset of adenocarcinomas, and more common in GAC, pointing to a potential benefit from trastuzumab treatment. HER2 overexpression does not identify gene amplification status in cervical adenocarcinoma; therefore, FISH is suggested for both IHC positive and equivocal cases. Further investigation on more cases with longer follow‐up times is required to consolidate these findings.Keywords
This publication has 36 references indexed in Scilit:
- HER2 Immunohistochemistry Significantly Overestimates HER2 Amplification in Uterine Papillary Serous CarcinomasAmerican Journal of Surgical Pathology, 2014
- Landscape of genomic alterations in cervical carcinomasNature, 2013
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapyBMC Cancer, 2009
- HER2/neu (c‐erbB‐2) gene amplification and protein expression are rare in uterine cervical neoplasia: a tissue microarray study of 814 archival specimensAPMIS, 2009
- Assessment of a HER2 scoring system for gastric cancer: results from a validation studyHistopathology, 2008
- Gastric Morphology and Immunophenotype Predict Poor Outcome in Mucinous Adenocarcinoma of the Uterine CervixAmerican Journal of Surgical Pathology, 2007
- Prognosis of adenocarcinoma of the uterine cervix: p53 expression correlates with higher incidence of mortalityInternational Journal of Cancer, 2007
- The role of TP53 in Cervical carcinogenesisHuman Mutation, 2003
- Prognostic significance of the overexpression of c-erbB-2 protein in adenocarcinoma of the uterine cervixCancer, 1994